Dr Chryso Kanthou
BSc, MPhil, PhD
Department of Oncology and Metabolism
+44 114 215 9052
Full contact details
Department of Oncology and Metabolism
The Medical School
Beech Hill Road
I joined the University of Sheffield in 2005 as Senior Lecturer in the Department of Oncology. Before joining Sheffield, I worked at the Gray Cancer Institute in Northwood, Middlesex, as senior scientist (1999-2005) and as post-doctoral scientist at the Thrombosis Research Institute in London (1994-1999).
In 1994, I and was awarded my PhD in Cell and Molecular Biology by the University of London. Before embarking on my PhD studies I worked as a research assistant at the Ludwig Institute for Cancer Research London and King´s College Hospital Medical School.
In addition to my PhD, I also hold a BSc degree in Cell Biology and an MPhil degree also in Cell Biology, both from King´s College, London.
- Research interests
My interests are in the field of endothelial vascular biology and angiogenesis. A main aim of my research is to understand the role played by factors within the tumour microenvironment in vessel network development and to decipher how this impacts on tumour response to vascular-targeted therapies.
I am particularly interested in studying molecular signalling pathways associated with the remodelling of the endothelial cytoskeleton, a target of vascular disrupting agents (VDAs) and ionizing radiation.
My research is part of a multidisciplinary approach aimed at investigating mechanisms at the molecular and cellular level that can then be tested at the level of the whole organism.
I am co-investigator on Professor Gillian Tozer´s `Tumour Microcirculation´ programme grant funded by Cancer Research UK. This programme focuses on the maturation phase of angiogenesis and interactions with vascular disrupting therapies.
The main aim is to investigate molecular mechanisms through which alternatively spliced variants of VEGF influence pericyte recruitment, differentiation and vessel stabilization and their relationship with endothelial responsiveness to VDAs.
Part of this work involves modeling the tumour microenvironment using co-culture systems of endothelial cells, pericytes and tumour cells under conditions of hypoxia and analysing signalling interactions.
I am principal investigator and work package leader on a collaborative European FP7-funded study investigating mechanisms of microvascular damage by ionizing radiation in the context of normal tissue damage, which is a crucial dose-limiting factor in radiotherapy.
Our main aim is to establish cellular and molecular mechanisms that mediate damaging effects of radiation on repair and angiogenesis within the microvasculature of the heart myocardium.
- Cover Feature: Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy (ChemMedChem 24/2018). ChemMedChem, 13(24), 2600-2600. View this article in WRRO
- Evaluation of Sydnone-Based Analogs of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy. ChemMedChem. View this article in WRRO
- Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes. Pharmaceutical Research, 35(4).
- The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget, 8, 95648-95661. View this article in WRRO
- Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. Cancer Research, 77(10). View this article in WRRO
- Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. J Med Chem, 59(20), 9473-9488. View this article in WRRO
- Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: Two case reports providing evidence for the role of preoperative LMWH in triggering sensitization. Thrombosis Research, 146, 126-130.
- Vascular endothelial growth factor (VEGF) isoform mediated tumour response to combination treatment with a blocking antibody to VEGFR-2 and radiotherapy. European Journal of Cancer, 61, S146-S146.
- Targeting the endoplasmic reticulum mediates radiation sensitivity in colorectal cancer. Experimental and Molecular Pathology, 98(3), 532-539.
- Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience. American Journal of Hematology, 90(7), 608-617.
- 19. Activation of the endoplasmic reticulum stress pathway and the radiosensitivity of human colorectal adenocarcinoma. European Journal of Surgical Oncology (EJSO), 40(11), S17-S17.
- An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.. Br J Pharmacol, 171(21), 4902-4913. View this article in WRRO
- Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.. Int J Cancer, 133(11), 2563-2576.
- The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner.. Blood, 120(25), 5073-5083.
- Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? a Cautionary Tale. PLoS ONE, 7(5). View this article in WRRO
- Abstract 5723: Inhibition of angiogenesis in the mouse heart by ionizing radiation. Experimental and Molecular Therapeutics.
- Abstract 1371: Delineating the function of single VEGF isoforms using both proteomic and molecular approaches. Tumor Biology.
- Abstract 5296: The role of VEGF receptors 1 and 2 on tumor vascularization and progression in single VEGF isoform expressing tumors. Tumor Biology.
- Inhibition of angiogenesis in the mouse heart by ionizing radiation. CANCER RESEARCH, 72.
- Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology.. Acta Biochim Pol, 58(3), 397-404.
- Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.. Int J Cancer, 129(8), 1979-1989.
- An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections.. J Microsc, 242(3), 262-278. View this article in WRRO
- Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.. Proc Natl Acad Sci U S A, 107(9), 3966-3971.
- Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.. Int J Exp Pathol, 90(3), 284-294.
- Tumour vascular disrupting agents: combating treatment resistance.. Br J Radiol, 81 Spec No 1, S12-S20.
- Measuring cellular migration with image processing. ELECTRON LETT, 44(13), 781-U27.
- Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.. Cancer Res, 68(7), 2301-2311.
- Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability.. Int J Radiat Oncol Biol Phys, 69(5), 1553-1562.
- Tumour targeting by microtubule-depolymerizing vascular disrupting agents.. Expert Opin Ther Targets, 11(11), 1443-1457.
- Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. Drug Discovery Today: Therapeutic Strategies, 4(4), 237-243.
- The endothelial cytoskeleton as a target of electroporation-based therapies.. Mol Cancer Ther, 5(12), 3145-3152.
- Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.. BMC Cancer, 6, 280. View this article in WRRO
- Disrupting tumour blood vessels.. Nat Rev Cancer, 5(6), 423-435.
- The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.. Am J Pathol, 165(4), 1401-1411.
- The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.. Anticancer Res, 23(4), 3199-3206.
- The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.. Blood, 99(6), 2060-2069.
- The biology of the combretastatins as tumour vascular targeting agents.. Int J Exp Pathol, 83(1), 21-38.
- Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy.. J Cell Biochem, 87(2), 221-232.
- Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions.. Mol Cancer Ther, 1(2), 151-160.
- Expression of vascular endothelial growth factor receptors in smooth muscle cells.. J Cell Physiol, 188(3), 359-368.
- Limitations of the reporter green fluorescent protein under simulated tumor conditions.. Cancer Res, 61(12), 4784-4790.
- The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin.. Blood, 95(6), 2008-2014.
- Cellular effects and signalling pathways activated by the anti-coagulant factor, protein S, in vascular cells protein S cellular effects.. Adv Exp Med Biol, 476, 155-166.
- Thrombin activates transcription factors sp1, NF-kappaB, and CREB: importance of the use of phosphatase inhibitors during nuclear protein extraction for the assessment of transcription factor DNA-binding activities.. Anal Biochem, 275(2), 180-186.
- Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders.. Arterioscler Thromb Vasc Biol, 17(11), 2848-2854.
- Evidence for cultured human vascular smooth muscle cell heterogeneity: isolation of clonal cells and study of their growth characteristics.. Thromb Haemost, 75(5), 854-858.
- Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells.. Cell Signal, 8(1), 59-66.
- Variability in the proliferative responsiveness of cultured human vascular smooth muscle cells to alpha-thrombin.. Blood Coagul Fibrinolysis, 6(8), 753-760.
- Prothrombin cleavage by human vascular smooth muscle cells: a potential alternative pathway to the coagulation cascade.. J Cell Biochem, 59(4), 514-528.
- Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells.. Thromb Haemost, 74(5), 1340-1347.
- Structural domains of thrombin involved in the induction of mitogenesis in cultured human vascular smooth muscle cells.. Blood Coagul Fibrinolysis, 6(7), 634-642.
- Long-term chemotaxis studies on adherent cells: effect of platelet-derived growth factor-BB on human vascular smooth muscle cell migration.. Anal Biochem, 230(2), 215-223.
- Evaluation of the use of the luciferase-reporter-gene system for gene-regulation studies involving cyclic AMP-elevating agents.. Biochem J, 309 ( Pt 2), 385-387.
- Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells.. Biochem J, 308 ( Pt 2), 481-485.
- The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density.. Lab Invest, 72(3), 376-382.
- Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells.. FEBS Lett, 314(2), 143-148.
- Use of low molecular weight heparin in pregnancy.. Thromb Haemost, 68(6), 652-656.
- Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. The British Journal of Radiology, 20180405-20180405.
- Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics. PLoS ONE, 9(8), e104015-e104015. View this article in WRRO
- Tumor vascular disrupting agents, Recent Advances in Angiogenesis and Antiangiogenesis (pp. 101-111).
- Vascular disrupting agents in cancer therapy. In Marmé D & Fusenig N (Ed.), Tumor angiogenesis: Basic Mechanisms and Cancer Therapy (pp. 809-829). Springer Verlag
- Heme-oxygenase and the novel tumour-specific anti-vascular compound combetastatin A-4-phosphate In Abraham NG (Ed.), Hemeoxygenase in Biology and Medicine (pp. 303-312). Springer
- Cellular and molecular effects of thrombin in the vascular system In Maragoudakis ME (Ed.), Angiogenesis (pp. 263-282). Springer
Conference proceedings papers
- Topological Analysis of the Vasculature of Angiopoietin-Expressing Tumours Through Scale-Space Tracing (pp 285-296)
- Abstract A57: Differential tumor cell expression of VEGF isoforms impacts on the tumor microenvironment, metastasis and radiation response in a mouse fibrosarcoma model. Translational and Therapeutic Potential of the Tumor Microenvironment
- Activation of the Endoplasmic Reticulum Stress Pathwaymay Enhance the Radiosensitivity of Human Colorectal Cancer Cells in Vitro. BRITISH JOURNAL OF SURGERY, Vol. 102 (pp 6-6)
- Analysis of Capillary-like Structures Formed by Endothelial Cells in a Novel Organotypic Assay Developed from Heart Tissue.. MIUA (pp 235-240)
- Abstract 1578: A critical role for RhoA-GTPase signaling in the tumor vascular disrupting action of combretastatin-A4-phosphatein vivo. Tumor Biology
- ABSTRACTS OF THE 59thMEETING OF THE BRITISH MICROCIRCULATION SOCIETY 30th– 31stMarch, 2009, The Medical School, University of Birmingham, UK. Microcirculation, Vol. 16(5) (pp 444-486)
- COLL 236-Dendrimeric nanocontainers as anti-angiogenic therapeutics. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol. 236
- The effects of radiation and the anti-vascular agent Combretastatin A-4-Phosphate on the cytoskeleton of human endothelial cells and on enclothelial monolayer permeability. RADIOTHERAPY AND ONCOLOGY, Vol. 73 (pp S326-S326)
- The role of tumour vascular maturation in determining response to tubulin-binding vascular targeting agents. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S60-S60)
- Combretastatin A-4-phosphate (CA-4-P) activates NFB in human endothelial cells.. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S28-S28)
- Effect of cell cycle on cellular HIF-1 alpha localisation. BRIT J CANCER, Vol. 86 (pp S99-S99)
- Effect of radiation and combretastatin A-4-P on cellular localisation of hypoxia inducible factor 1. 22ND MEETING OF THE EUROPEAN SOCIETY FOR MICROCIRCULATION: MICROCIRCULATION AND VASCULAR BIOLOGY (pp 19-23)
- Nitrotyrosination of endothelial alpha-tubulin: Potential effects on binding of the tumour vascular-targeting agent, combretastatin A-4-P. 22ND MEETING OF THE EUROPEAN SOCIETY FOR MICROCIRCULATION: MICROCIRCULATION AND VASCULAR BIOLOGY (pp 33-37)
- Haem oxygenase and Combretastatin A4-Phosphate vascular damage. BRIT J CANCER, Vol. 85 (pp 35-35)
- In vitro characterization of the novel tumour vascular targeting agent ZD6126. BRIT J CANCER, Vol. 83 (pp 31-31)
- Studies on the mechanism of action of the vascular targeting agent combretastatin A-4 phosphate. BRIT J CANCER, Vol. 83 (pp 12-12)
- Thrombin activates transcription factors Sp1, NF-kappa B and CREB. Importance of the nuclear protein extraction procedure in the assessment of transcription factor DNA binding activities. THROMB HAEMOSTASIS (pp 299-299)
- Protein S is expressed by cultured human vascular smooth muscle cells (HVSMC). THROMB HAEMOSTASIS (pp 564-564)
- Identification of annexin-II as a receptor for the anti-coagulant factor, protein S, in human vascular smooth muscle cells. THROMB HAEMOSTASIS (pp 215-215)
- The anticoagulant factor protein S acts as a survival factor for cultured human vascular smooth muscle cells (HVSMC). THROMB HAEMOSTASIS (pp 241-242)
- Differential effects of growth factors on gap junction expression in cultured human aortic smooth muscle cells. ATHEROSCLEROSIS, Vol. 136 (pp S51-S51)
- Cellular and molecular effects of thrombin in the vascular system.. ANGIOGENESIS, Vol. 298 (pp 263-282)
- Heparin induces release of intracellular tissue factor pathway inhibitor from human endothelial cells in culture. THROMB HAEMOSTASIS (pp P2312-P2312)
- Urokinase-type plasminogen activator in vasoproliferative disorders: Induction of vascular smooth muscle cell proliferation indicates a novel mechanism of action. THROMB HAEMOSTASIS (pp O2377-O2377)
- Interactions of tissue type plasminogen activator (t-PA) with human vascular smooth muscle cells. THROMB HAEMOSTASIS (pp O1635-O1635)
- Induction of human vascular smooth muscle cell proliferation by protein S: Binding studies and mechanism of action. THROMB HAEMOSTASIS (pp P2278-P2278)
- Induction of vascular smooth muscle cell proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders.. FASEB J, Vol. 11(3) (pp 898-898)
- Decreased expression of low density lipoprotein related protein (lrp) by the neointimal smooth muscle cells in rabbit balloon-injured abdominal aorta. Fibrinolysis, Vol. 10(SUPPL. 3) (pp 11)
- Expression of some components of plasminogen activation (pa) pathway by arterial segments in organ culture after in vitro injury. Fibrinolysis, Vol. 10(SUPPL. 3) (pp 4)
- CONVERSION OF PROTHROMBIN TO AN ENZYMATICALLY AND MITOGENICALLY ACTIVE FORM AT THE SURFACE OF HUMAN VASCULAR SMOOTH-MUSCLE CELLS. THROMB HAEMOSTASIS, Vol. 73(6) (pp 911-911)
- EVIDENCE FOR PROTEIN-S RECEPTOR(S) ON HUMAN VASCULAR SMOOTH-MUSCLE CELLS - ANALYSIS OF THE BINDING CHARACTERISTICS AND MITOGENIC PROPERTIES OF PROTEIN-S ON HUMAN VASCULAR SMOOTH-MUSCLE CELLS. THROMB HAEMOSTASIS, Vol. 73(6) (pp 939-939)
- ENDOTHELIN (ET) IS A MITOGEN FOR HUMAN VASCULAR SMOOTH-MUSCLE CELLS (HVSMC). THROMB HAEMOSTASIS, Vol. 69(6) (pp 971-971)
- SUPPRESSION OF HUMAN VASCULAR SMOOTH-MUSCLE CELL (HVSMC) PROLIFERATION BY VITRONECTIN. THROMB HAEMOSTASIS, Vol. 69(6) (pp 971-971)
- SIGNAL-TRANSDUCTION MECHANISMS INVOLVED IN THE MITOGENIC ACTIVITY OF THROMBIN IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS (HVSMC). THROMB HAEMOSTASIS, Vol. 69(6) (pp 802-802)
- INHIBITION OF THROMBIN-INDUCED HUMAN VASCULAR SMOOTH CELL (HVSMC) PROLIFERATION BY INHIBITORS OF THROMBIN. THROMB HAEMOSTASIS, Vol. 69(6) (pp 804-804)
- INHIBITION OF CELL-PROLIFERATION BY HEPARIN. THROMB HAEMOSTASIS, Vol. 65(6) (pp 993-993)
- THE ROLE OF THROMBIN ON HUMAN VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION. THROMB HAEMOSTASIS, Vol. 65(6) (pp 732-732)
- THE USE OF LMW HEPARIN IN TREATING THROMBOEMBOLISM DURING PREGNANCY AND PREVENTION OF OSTEOPOROSIS. THROMB HAEMOSTASIS, Vol. 65(6) (pp 926-926)
- PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE ACTIVATION AND GROWTH-FACTOR PRODUCTION BY HUMAN AORTIC SMOOTH-MUSCLE CELLS. THROMB HAEMOSTASIS, Vol. 58(1) (pp 261-261)
- ATHEROMA - A NEW HYPOTHESIS. BRIT J SURG, Vol. 74(6) (pp 526-526)
- MODIFICATION OF PLATELET-DERIVED GROWTH-FACTOR BY ANTIPLATELET THERAPY AND ITS RELATIONSHIP TO VASCULAR GRAFT PATENCY. THROMB HAEMOSTASIS, Vol. 54(1) (pp 280-280)
- COMPARISON OF 3 MOLECULAR-WEIGHT FRACTIONS OF HEPARIN FOR THEIR ABILITY TO MODIFY PIG AORTIC SMOOTH-MUSCLE CELL (PASM) PROLIFERATION IN CULTURE. THROMB HAEMOSTASIS, Vol. 54(1) (pp 97-97)
- Research group
- Zahra Gharaei
- Venkata Satish Kolli
- Teaching interests
I supervise and co-supervise several PhD, MSc and BMed Sciences students and Clinical Research Fellows.
I lecture on the MSc Molecular Medicine course at the School of Medicine in Sheffield, an MSc Radiation Biology course at University College London, and MSc Oncology course at the University of Nottingham. I also tutor MSc students and mentor PhD and Medical students.
- Professional activities
I am a member of a sub-group of the Advisory Group on Ionising Radiation set up by the Health Protection Agency to consider circulatory disease risks of radiation and perform critical appraisal (since April 2008). I am also currently a member of the executive committee of the British Association for Cancer Research.